Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Jon C. Ogg | Jul 1, 2015 at 11:05 AM EDT

Teladoc Debuts Strong in IPO

Teladoc was set to be the first initial public offering (IPO) of its kind. The company claims to be the…

Chris Lange | Jun 30, 2015 at 8:10 AM EDT

What Celgene Now Means for Juno

Celgene and Juno Therapeutics are coming together in a global collaboration for the development and commercialization of immunotherapies.

Chris Lange | Jun 29, 2015 at 3:20 PM EDT

Sarepta Takes Its Foot off the Gas

Sarepta Therapeutics announces the completion of the rolling submission of a New Drug Application to the FDA for eteplirsen.

Jon C. Ogg | Jun 29, 2015 at 10:50 AM EDT

Do Health Insurance Mergers Really Need to Sweat DOJ Reviews?

The U.S. Department of Justice is now said to be set to give a very close review of any of…

Chris Lange | Jun 26, 2015 at 11:35 AM EDT

Is Big Pharma Advertising Getting Out of Control?

How much are big pharmaceutical companies really spending to get their drugs out there in the public eye?

Paul Ausick | Jun 26, 2015 at 11:10 AM EDT

Are Cancer Drugs Becoming Too Costly for Their Effectiveness?

When the American Society of Clinical Oncology (ASCO) decided to create a rating scale for cancer drugs, it certainly must…

Chris Lange | Jun 26, 2015 at 10:40 AM EDT

Can Celladon Weather the Storm?

Celladon is continuing to seek out a merger partner, and at the same time, it is not pursuing the further…

Trey Thoelcke | Jun 25, 2015 at 10:05 AM EDT

CAR T-Cell Stocks a Better Way to Leverage Biotech Than New 3x ETFs

If you missed the biotech run and want to try to catch the train this late in the game, it…

Chris Lange | Jun 25, 2015 at 8:10 AM EDT

Short Sellers Become More Focused on Big Pharma

The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short…

Chris Lange | Jun 25, 2015 at 7:50 AM EDT

Short Sellers Get More Selective on Big Biotech

The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech…

Jon C. Ogg | Jun 24, 2015 at 12:10 PM EDT

Ritter Debuts Quietly in IPO Launch

Ritter Pharmaceuticals is the latest company to join in on the wave of initial public offerings.

Jon C. Ogg | Jun 23, 2015 at 1:00 PM EDT

Triple Leverage ETFs Launched in Biotech

For active traders and investors looking for juiced up returns in the hot biotech sector, ProShares has launched two triple…

Jon C. Ogg | Jun 23, 2015 at 11:35 AM EDT

Oral Testosterone Pill Could Make Lipocine Worth Substantially More

Lipocine may have a huge hit on its hands with the first swallowable oral testosterone treatment.

Chris Lange | Jun 23, 2015 at 9:55 AM EDT

How MELA Plans to Buy XTRAC and VTRAC From PhotoMedex

PhotoMedex has announced that it will be selling its XTRAC and VTRAC psoriasis and vitiligo treatment businesses to MELA Sciences.

Jon C. Ogg | Jun 23, 2015 at 6:34 AM EDT

Benitec From Australia Files for US IPO: Gene Silencing and Gene Therapy

Benitec Biopharma, a clinical-stage biotechnology outfit, has filed for an initial public offering in the United States.

1 … 258 259 260 261 262 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Teladoc Debuts Strong in IPO

What Celgene Now Means for Juno

Sarepta Takes Its Foot off the Gas

Do Health Insurance Mergers Really Need to Sweat DOJ Reviews?

Is Big Pharma Advertising Getting Out of Control?

Are Cancer Drugs Becoming Too Costly for Their Effectiveness?

Can Celladon Weather the Storm?

CAR T-Cell Stocks a Better Way to Leverage Biotech Than New 3x ETFs

Short Sellers Become More Focused on Big Pharma

Short Sellers Get More Selective on Big Biotech

Ritter Debuts Quietly in IPO Launch

Triple Leverage ETFs Launched in Biotech

Oral Testosterone Pill Could Make Lipocine Worth Substantially More

How MELA Plans to Buy XTRAC and VTRAC From PhotoMedex

Benitec From Australia Files for US IPO: Gene Silencing and Gene Therapy

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Health and Healthcare Articles

All Health and Healthcare Articles

Teladoc Debuts Strong in IPO

What Celgene Now Means for Juno

Sarepta Takes Its Foot off the Gas

Do Health Insurance Mergers Really Need to Sweat DOJ Reviews?

Is Big Pharma Advertising Getting Out of Control?

Are Cancer Drugs Becoming Too Costly for Their Effectiveness?

Can Celladon Weather the Storm?

CAR T-Cell Stocks a Better Way to Leverage Biotech Than New 3x ETFs

Short Sellers Become More Focused on Big Pharma

Short Sellers Get More Selective on Big Biotech

Ritter Debuts Quietly in IPO Launch

Triple Leverage ETFs Launched in Biotech

Oral Testosterone Pill Could Make Lipocine Worth Substantially More

How MELA Plans to Buy XTRAC and VTRAC From PhotoMedex

Benitec From Australia Files for US IPO: Gene Silencing and Gene Therapy

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how